Adcetris (brentuximab vedotin) is the market-leading drug in the world’s 7MM (the USA, France, Germany, Italy, Spain, the UK and Japan) markets and the main contributor to the market growth in Hodgkin’s lymphoma (HL) over the recent years.
Adcetris is being jointly developed and marketed by Japanese drugmaker Takeda (TYO: 4502) and US biotech Seattle Genetics (Nasdaq: SGEN),
The initial patent expiry in the USA in 2024 is expected to lead to stagnation in this currently growing market. However, this could be compensated by a new competitive landscape which will provide an opportunity for new companies looking to enter the HL market, says data and analytics company GlobalData.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze